Stock Code: Guangdong Vtr Bio-Tech Co.Ltd(300381) stock abbreviation: Guangdong Vtr Bio-Tech Co.Ltd(300381)
Bond Code: 123018 bond abbreviation: profit convertible bond Announcement No.: 2022040 Guangdong Vtr Bio-Tech Co.Ltd(300381)
Announcement on terminating the issuance of convertible corporate bonds to unspecified objects
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
On April 22, 2022, the 17th meeting of the 7th board of directors and the 11th meeting of the 7th board of supervisors held by Guangdong Vtr Bio-Tech Co.Ltd(300381) (hereinafter referred to as “the company”) deliberated and adopted the proposal on terminating the issuance of convertible corporate bonds to unspecified objects. The specific contents are hereby announced as follows:
1、 Basic information of convertible corporate bonds issued this time
In order to broaden the company’s financing channels, optimize the financing structure, reduce financing risks and costs, and meet the company’s capital needs for operation and development, combined with the bond market and the company’s capital needs at that time, the company held the 52nd meeting of the sixth board of directors and the 41st meeting of the sixth board of supervisors on January 28, 2021, and deliberated and approved the relevant proposals of the company on issuing convertible corporate bonds to unspecified objects.
Combined with the actual situation of the company, the sixth meeting of the seventh board of directors and the sixth meeting of the seventh board of supervisors held by the company on June 30, 2021 considered and adopted the relevant proposal to amend the convertible bonds. The issuance of convertible corporate bonds to unspecified objects has not been deliberated by the general meeting of shareholders.
2、 Reasons for terminating the issuance of convertible corporate bonds
In view of the continuous investment of a large amount of funds for the development of the company’s biomedical sector and the great capital pressure on the company, the company held the 13th meeting of the seventh board of directors and the 9th meeting of the seventh board of supervisors on January 28, 2022, and the first extraordinary general meeting of shareholders in 2022 on March 31, 2022 to consider and adopt the proposal on the sale of major assets and related party transactions of the company and other proposals, Agree to sell all assets related to biomedical business, that is, sell all the equity of Hunan xinhexin biomedical Co., Ltd., Hunan keyixin biomedical Co., Ltd. and Henan Lihua Pharmaceutical Co., Ltd. in cash. After the above assets are sold, the company’s business will change greatly. Therefore, combined with the current actual situation of the company, the company decides to terminate the issue of convertible corporate bonds to unspecified objects.
3、 Impact of terminating the issuance of convertible corporate bonds on the company
The company’s termination of issuing convertible corporate bonds to unspecified objects will not affect the normal operation of the company’s existing business, will not adversely affect the sustainable and stable development of the company, and will not damage the interests of the company’s shareholders, especially the minority shareholders.
4、 Opinions of independent directors
The company’s decision to terminate the issuance of convertible corporate bonds to unspecified objects is made according to the actual situation of the company, which will not have a significant adverse impact on the operation and sustainable and stable development of the company, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders. The board of directors of the company performed the necessary procedures when deliberating the proposal, and complied with the relevant laws and regulations, the articles of association and other relevant provisions. Therefore, we unanimously agree on the contents of the motion.
It is hereby announced.
Guangdong Vtr Bio-Tech Co.Ltd(300381) board of directors
April 23, 2022
